Recent Updates
Recently added Catalysts
FATE Negative Sentiment

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Fate Therapeutics, Inc. is under investigation by Bragar Eagel & Squire, P.C. for potential claims following a class action lawsuit. The investigation is focused on whether the board breached fiduciary duties after a series of negative developments, including the termination of its collaboration with Janssen and significant layoffs. The class action lawsuit alleges failure to disclose material information regarding these critical events. Consequently, long-term stockholders are encouraged to reach out for more information regarding their rights and potential claims.
Price reaction · baseline $2.39 (2023-11-03 close) · hit after-hours · 1 other FATE headline(s) in the window, move may be shared
day 0 close
+5%
day 1
-3.3%
day 3 · peak
-10.9%

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action complaint filed against Fate Therapeutics raises concerns.
  • Termination of collaboration agreement with Janssen may impact future potential.
  • Reduction of workforce indicates possible financial instability.
  • Discontinuation of cancer treatment programs suggests challenges in product pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+218%
120-day peak, hindsight
Typical move
10.6%
average across 6 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
FT836
Phase 1 · Non-Small Cell Lung Cancer

Full Press Release Details

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders following a class action complaint that was filed against Fate on January 20, 2023 with a Class Period from April 2, 2020 to January 5, 2023. Our investigation concerns whether the board of directors of Fate have breached their fiduciary duties to the company.
On April 2, 2020, the Company announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment and was eligible for up to $3 billion in various milestone payments and double-digit royalties on any net sales from the collaboration. Then, on January 5, 2023, the Company disclosed that it had terminated the Janssen Agreement and that all licenses and other rights granted pursuant to the Agreement would terminate, that it would reduce its headcount to about 220 employees in Q1 2023, and that it would discontinue several of its natural cell killer programs in various cancers.
Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains pending.
If you are a long-term stockholder of Fate, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What is the lawsuit against Fate Therapeutics about?

The lawsuit investigates whether Fate's board violated fiduciary duties to stockholders.

When was the class action complaint filed against Fate?

The class action complaint was filed on January 20, 2023.

What significant event happened on January 5, 2023?

Fate Therapeutics announced the termination of its collaboration with Janssen.

How can long-term stockholders contact Bragar Eagel & Squire?

They can reach out via email at investigations@bespc.com or call (212) 355-4648.

What type of law firm is Bragar Eagel & Squire, P.C.?

It is a nationally recognized law firm specializing in securities and complex litigation.

Last updated: Nov 4, 2023